Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M.

J Clin Oncol. 1998 Apr;16(4):1248-55. Erratum in: J Clin Oncol 1998 Aug;16(8):2895.

PMID:
9552022
2.

Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.

Stegmaier S, Leuschner I, Aakcha-Rudel E, Münch P, Kazanowska B, Bekassy A, Treuner J, Koscielniak E.

Klin Padiatr. 2004 Nov-Dec;216(6):315-22.

PMID:
15565546
3.

Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.

Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H.

J Clin Oncol. 2010 Apr 20;28(12):1982-8. doi: 10.1200/JCO.2009.23.3585. Epub 2010 Mar 22.

PMID:
20308673
4.

Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.

Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M.

Cancer Res. 1999 Apr 1;59(7):1428-32.

5.

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.

van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER.

J Clin Oncol. 2010 Apr 20;28(12):1989-94. doi: 10.1200/JCO.2009.24.5845. Epub 2010 Mar 22.

6.

Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindán FJ, Barr FG, Ladanyi M.

Am J Pathol. 2000 Mar;156(3):849-55.

7.

EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma.

Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M, Zoubek A, Dockhorn-Dworniczak B, Juergens H, Wunder JS, Andrulis IL, Malik R, Sorensen PH, Womer RB, Barr FG.

J Clin Oncol. 1999 Jun;17(6):1809-14.

PMID:
10561219
8.

Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, Smith TL, Jürgens H, Gadner H, Kovar H.

J Clin Oncol. 1996 Apr;14(4):1245-51.

PMID:
8648380
9.

Variability in gene expression patterns of Ewing tumor cell lines differing in EWS-FLI1 fusion type.

Aryee DN, Sommergruber W, Muehlbacher K, Dockhorn-Dworniczak B, Zoubek A, Kovar H.

Lab Invest. 2000 Dec;80(12):1833-44.

PMID:
11140696
10.

FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.

Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA.

Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34. doi: 10.1016/j.bbrc.2010.09.129. Epub 2010 Oct 8.

11.

[Detection of EWS-FLI1 fusion transcript in Ewing's sarcoma/peripheral primitive neuroectodermal tumors by one-step RT-PCR using paraffin-embedded tissues].

Li F, Chang B, Li XX, Pang LJ, Lu HF, Wang J, Sun MH, Shi DR.

Zhonghua Bing Li Xue Za Zhi. 2004 Aug;33(4):328-31. Chinese.

PMID:
15363317
12.

EWS-FLI1 fusion transcripts identified in patients with typical neuroblastoma.

Burchill SA, Wheeldon J, Cullinane C, Lewis IJ.

Eur J Cancer. 1997 Feb;33(2):239-43. Erratum in: Eur J Cancer 1997 Oct;33(11):1907. Eur J Cancer 1997 Jul;33(8):1337.

PMID:
9135495
13.

The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.

Vural C, Uluoğlu O, Akyürek N, Oğuz A, Karadeniz C.

Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 2011 Jan 26.

PMID:
21267687
14.

Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.

Uren A, Toretsky JA.

Future Oncol. 2005 Aug;1(4):521-8. Review.

PMID:
16556028
15.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

16.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
17.

EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.

Ban J, Siligan C, Kreppel M, Aryee D, Kovar H.

Adv Exp Med Biol. 2006;587:41-52. Review.

PMID:
17163154
18.

Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples.

de Alava E, Lozano MD, Patiño A, Sierrasesúmaga L, Pardo-Mindán FJ.

Diagn Mol Pathol. 1998 Jun;7(3):152-7.

PMID:
9836070
20.

EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.

Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, Emanuel BS, Evans GA.

J Clin Invest. 1994 Aug;94(2):489-96.

Supplemental Content

Support Center